Levodopa Induced Dyskinesia (LID): Clinical Trials

4 trials for Levodopa Induced Dyskinesia (LID), newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

3 completed, 1 terminated. 3 Phase 3, 1 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 33Completed 2, Terminated 1
Phase 21Completed 1

Follow Levodopa Induced Dyskinesia (LID): new trials by email Literature Review of Levodopa Induced Dyskinesia (LID) trials Research Report on Levodopa Induced Dyskinesia (LID)

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Efficacy and Safety of JM-010 in PD With Levodopa-Induced Dyskinesia
JM-010, Placebo - Parkinson's Disease, Levodopa Induced Dyskinesia (LID)
Phase 2CompletedBukwang Pharmaceutical302015-05-012016-01-13
Efficacy and Safety of Amantadine Hydrogen Chloride (HCl) ER Tablets in Parkinson's Disease Subjects With LID
amantadine HCl ER, Placebo - Parkinson's Disease, Levodopa Induced Dyskinesia (LID)
Phase 3TerminatedAdamas Pharmaceuticals, Inc.1352014-07-302022-02-16
Open-Label Safety Study of ADS-5102 in PD Patients With LID
ADS-5102 - Dyskinesia, Levodopa Induced Dyskinesia (LID)
Phase 3CompletedAdamas Pharmaceuticals, Inc.2232014-07-012020-10-06
ADS-5102 for the Treatment of Levodopa Induced Dyskinesia (EASE LID Study)
ADS-5102, Placebo - Dyskinesia, Levodopa Induced Dyskinesia (LID)
Phase 3CompletedAdamas Pharmaceuticals, Inc.1262014-05-012018-02-06

Narrower conditions

Dyskinesias (4)  ·  Parkinson Disease (4)  ·  Parkinsonian Disorders (3)

Broader conditions

Basal Ganglia Diseases (4)  ·  Brain Diseases (4)  ·  Central Nervous System Diseases (4)  ·  Movement Disorders (4)  ·  Nervous System Diseases (4)  ·  Neurodegenerative Diseases (4)  ·  Neurologic Manifestations (4)  ·  Pathological Conditions, Signs and Symptoms (4)  ·  Signs and Symptoms (4)  ·  Synucleinopathies (4)  ·  Parkinsonian Disorders (1)

Interventions

Amantadine (1)

Sponsors

Adamas Pharmaceuticals, Inc. (3)  ·  Bukwang Pharmaceutical (1)

Countries

Canada (3)  ·  United States (3)  ·  France (2)  ·  Germany (2)  ·  Spain (2)  ·  Austria (1)  ·  South Africa (1)

Top investigators

Angela Dentiste, MBA (1)

Results publications

PMID 28604926, PMID 28777755, PMID 29532440, PMID 33864229, PMID 34024025